Trial Profile
A study evaluating of some BCR/ABL1-independent molecular predictive markers of response in Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (Imatinib, Nilotinib, Dasatinib)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- 22 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association